Schizophrenia News and Research

Latest Schizophrenia News and Research

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA.

29 Dec 2014

Intriguing small molecule directs activity of key ‘clock proteins’

In research published in Nature Communications, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports intriguing findings about a small molecule that directs the activity of key "clock proteins," offering the potential to manage circadian rhythm and treat problems that are associated with its dysfunction, like sleep and anxiety disorders.

24 Dec 2014

Social environment not linked to UHR psychosis transition

Research indicates that social deprivation and migrant status do not influence the risk of transition to psychosis in ultra-high-risk individuals.

18 Dec 2014

Health promotion program reduces cardiovascular risk in obese people with serious mental illness

A health promotion program, called In SHAPE, specifically designed for people with serious mental illness, produced more fit participants and significant weight loss than a control group where participants only received a gym membership.

18 Dec 2014

New study finds high suicide rates among transgender veterans

Veterans of the U.S. armed forces who have received a diagnosis consistent with transgender status are more likely to have serious suicidal thoughts and plans and to attempt suicide.

18 Dec 2014

Antipsychotic polypharmacy prevalent despite efficacy doubts

Results of a retrospective study suggest that around a quarter of patients with schizophrenia receive antipsychotic polypharmacy, despite a lack of evidence for the approach.

17 Dec 2014

Novel technique to identify biological markers in brain development

With a unique, multi-faceted approach, researchers at the Lieber Institute for Brain Development have quantified the effect of previously unidentified anomalies in genetic expression that determine how the human brain develops from its earliest stages.

17 Dec 2014

Cerebellar cortical volume reduction specific to schizophrenia

Reduced cerebellar cortical volume occurs only in patients with schizophrenia, rather than all those with psychosis, say researchers.

10 Dec 2014

Novel drug target could lead to better antipsychotic medications

Scientists at the Centre for Addiction and Mental Health have identified a novel drug target that could lead to the development of better antipsychotic medications.

10 Dec 2014

Excess mortality in schizophrenia ‘not attributable to antipsychotics’

The relationship between antipsychotic use and mortality in people with schizophrenia shows a clear U-shape curve, with the highest risk of death seen in those with no antipsychotic exposure, a Swedish cohort study has found.

9 Dec 2014

New study investigates rate of HIV testing in patients with mental illnesses

People with mental illness are more likely to have been tested for HIV than those without mental illness, according to a new study from a team of researchers at Penn Medicine and the U.S. Centers for Disease Control and Prevention published online this week in AIDS Patient Care and STDs.

5 Dec 2014

People with first-episode psychosis may benefit from medication treatment changes, study finds

Many patients with first-episode psychosis receive medications that do not comply with recommended guidelines for first-episode treatment, researchers have found. Current guidelines emphasize low doses of antipsychotic drugs and strategies for minimizing the side effects that might contribute to patients stopping their medication.

5 Dec 2014

IQ linked to schizophrenia risk

The risk for developing schizophrenia is significantly affected by an individual’s IQ, show results of a study of over 1 million Swedish men.

3 Dec 2014

Early intervention benefits may not stay the course in psychosis

Most of the benefits of a specialised early intervention for psychosis have disappeared by 8 years after its completion, shows follow-up of the OPUS trial.

27 Nov 2014

Researchers uncover easily detectable, 'pre-malignant' state in the blood

Researchers from the Broad Institute of MIT and Harvard, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, "pre-malignant" state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome.

27 Nov 2014

Study shows how mentally ill women in India go through a vicious cycle

An award-winning study by a Loyola University Chicago Stritch School of Medicine researcher has documented how homeless, mentally ill women in India face a vicious cycle

26 Nov 2014

Research findings could provide insight into how doctors could restore human memory

UCLA neurophysicists have found that space-mapping neurons in the brain react differently to virtual reality than they do to real-world environments. Their findings could be significant for people who use virtual reality for gaming, military, commercial, scientific or other purposes.

25 Nov 2014

NOS1AP gene may help explain biological process of schizophrenia

A gene associated with schizophrenia plays a role in brain development and may help to explain the biological process of the disease, according to new Rutgers research.

24 Nov 2014

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") is pleased to announce that it has closed a brokered private placement offering (the "Brokered Offering") of special warrants for approximately C$3.7 million.

21 Nov 2014

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults.

19 Nov 2014